行业质量体系在药品CGMP法规方面的指导原则(中文)
VIP免费
CGMP
CDER
CBER
CVM
ORA
2006 9
CGMP
CGMP
HFD-240
5600
20857
301-827-4573
http://www.fda.gov/cder/guidance/index.htm
HFM-40
1401
20852-1448 http://www.fda.gov/cber/guidelines.
htm.800-835-4709 301-827-180
HFV-12
7519 2085
301-827-380
http://www.fda.gov/cvm/guidance/published.html
CDER
CBER
CVMORA
2006 9 CGMP
Contains Nonbinding Recommendations
. ....................................................................................................................................... 1
II. ............................................................................................................................ 1
A. .....................................................................................................................................................................1
B. .........................................................................................................................................................2
C. .........................................................................................................................................................3
D. .............................................................................................................................................4
III. CGMPS ........................................................................................... 4
A. ......................................................................................................................................................................4
B. .............................................................................................................................4
C. .....................................................................................................................................................5
D. CAPA...............................................................................................................................5
E. .............................................................................................................................................................5
F. .............................................................................................................................................................5
G. ..................................................................................................................................................6
IV. ....................................................................................................................... 8
A. .............................................................................................................................................................8
1. .........................................................................................................................................................8
2. ............................................................................................................................................................9
3. .......................................................................................................................9
4. .....................................................................................................................................10
5. ...........................................................................................................................................................10
B. ...................................................................................................................................................................12
1. ...........................................................................................................................................................12
2. ...........................................................................................................................................................13
3. ........................................................................................................................................................13
4. ..................................................................................................................................................14
C. ..................................................................................................................................................................15
1. ..........................................................................................................................15
2. ..........................................................................................................................................................16
3. .............................................................................................................................................17
4. ...................................................................................................................................................19
D. ............................................................................................................................................................21
1. ......................................................................................................................................21
2. ....................................................................................................................................................21
3. ..................................................................................................................................................22
4. ............................................................................................................................................................22
摘要:
展开>>
收起<<
oTCGMPlvOSelLNcSWVSkuNQlOgRToTvwctoTNTxzvNCDERuriR6TO0xzvNCBERQoNCVMvNRRQlORA2006t9goTuNtCGMPoTCGMPlvOSelLNcSWYvRogSNNNnSSWNlRQloTOoYHFD240oTNTxzvNToTvwct95600SlQpWQK20857Su53018274573httpwwwfdagovcderguidanceindexhtmb0WNRQluriR6TO0xzvNHFM40R6UFSORToTvwct1401WQKYSWQKlQp208521448httpwwwfdagovcberguid...
声明:如果您的权利被侵害,请联系我们的进行举报。
相关推荐
-
ISO17025:2017一整套程序文件(实验室认可服务)VIP免费
2024-06-05 113 -
医疗器械工作程序文件VIP免费
2024-12-10 158 -
确认与验证管理规程VIP免费
2025-04-21 51 -
有害物质管理程序(含表格)VIP免费
2025-05-04 70 -
医疗器械上市后临床跟踪控制程序VIP免费
2025-10-27 46 -
供应商质量管理程序VIP免费
2025-11-07 64 -
DC2-07001 设备设施控制程序VIP免费
2026-03-21 10 -
DC2-07001 设备设施控制程序1VIP免费
2026-03-21 8 -
DC2-08001 与顾客有关的过程控制程序VIP免费
2026-03-21 6 -
DC2-09001 环境因素识别、评价与控制程序VIP免费
2026-03-21 12
作者:冒牌货
分类:专业资料
价格:150质量币
属性:32 页
大小:6.42MB
格式:PDF
时间:2025-12-04

